Matinas Biopharma Holdings, Inc. (OTCQB: MTNB), is a biopharmaceutical company still in its clinical stages, focused on identifying and developing treatments for fungal and bacterial infections. Founded in 2012, the company’s goal is to change the way in which potent medicines are delivered and administered, with the aim of giving both physicians and patients better, safer, and more effective solutions to fight these infections.
MTNB is working toward unique benefits through its lead drug candidates, MAT2501 and MAT2203. These benefits include oral administration and bioavailability, multi-organ protection, and targeted delivery directly to the infected areas. MAT2501 is used to treat gram negative bacterial infections, and MAT2203 is a drug used in patients with refractory mucocutaneous candidiasis.
Most recently, the company announced that it has started enrollment and that the first group of patients have been dosed in its phase II clinical study of MAT2203. The phase II study is a randomized, multicenter, evaluator blinded study for which approximately 75 patients will be enrolled. In addition, the company is in the process of evaluating the drug in a phase IIa open label dose titration study. The study is being undertaken to establish whether or not the drug is efficient, safe, and tolerable for patients with a long standing or recurrent mucocutaneous candidiasis infection.
As a result of this progression, Aegis Capital Corp. (http://dtn.fm/6twE7) recently updated the company to a ‘Buy’ rating with a target price of $8 per share based on its estimated FY2022 EPS of $2.55 per share. This news came after the company reported that its coming milestones for the phase II study of MAT2203 and phase I study of MAT2501 are on schedule. However, Aegis is not the only one to review Matinas Biopharma Holdings, Inc.
Earlier this month, Maxim Group (http://dtn.fm/U33oS) initiated coverage on Matinas BioPharma Holdings, Inc., offering the company a ‘Buy’ rating. In addition to these reports, MarketExclusive.com (http://dtn.fm/8JMoT) stated that if the company succeeds in its phase II trial, it could take over Gilead’s $350 million market for its own version of the drug. According to a report from The Cerbat Gem Market News and Analysis (http://dtn.fm/UOh4i), MTNB has been trading at approximately $1.54 per share with a trading volume of 25,525 shares. The company’s market cap stands at $88.23 million.
For more information, visit the company’s website at www.MatinasBioPharma.com
This post first appeared on Monaker Group, Inc. (MKGI) Carves Niche In Explosi, please read the originial post: here